Palisade Bio, Inc. - Common Stock PALI 深 滬
等待開盤 10-04 09:30:00 美东时间
1.60
-0.100
-5.88%
華盛通- 最 高1.86
- 今 開1.85
- 成交量 2066.86万股
- 最 低 1.52
- 昨 收 1.70
- 總市值 1459.07万
- 52周最高 4.318
- 市盈率 靜 --
- 換手率 226.65%
- 52周最低 0.53
- 委 比 9.47%
- 總股本 911.92万
- 歷史最高 18405.00
- 量 比 0.53
- 振 幅 20.00%
- 歷史最低 0.53
- 每 手 1
- 風險率 2.04%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Palisades Goldcorp任命新任首席财务官
以资源行业为核心的加拿大商业银行Palisades Goldcorp（PALI）周五宣布任命杰夫·施蒂伯（Jeff Stieber）为首席财务官，接替巴萨姆...
10-02 23:05
Palisades Goldcorp gets new finance chief
Palisades Goldcorp (TSXV:PALI:CA) appointed Jeff Stieber as the company's CFO, effective immediately. The appointment of Mr. Stieber follows the resignation of Bassam Moubarak from the post. Mr. Stieb...
10-02 16:41
Palisade Bio shares are trading lower after the company priced a $120M public offering of 171.4M shares at $0.70 per share.
Palisade Bio shares are trading lower after the company priced a $120M public o...
10-01 21:24
Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock
Palisade Bio, Inc. announced the pricing of an underwritten public offering of 171,440,559 shares of its common stock at $0.70 per share, generating approximately $120 million in gross proceeds. Ladenburg Thalmann & Co. Inc. is the sole book-running manager. The company also granted underwriters a 45-day option to purchase up to an additional 25,714,285 shares. The offering is expected to close on October 2, 2025, subject to customary conditions....
10-01 13:20
Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum
Palisade Bio's special stockholder meeting on September 18, 2025, was adjourned due to lack of quorum, as fewer than one-third of outstanding shares were present. The meeting will reconvene on September 26, 2025, in a virtual format. The company continues to seek votes for its proposals outlined in the Proxy Statement filed on August 18, 2025. Stockholders of record as of July 28, 2025, are encouraged to vote by September 25, 2025. If insufficien...
09-18 20:05
Palisade Bio Releases PALI-2108 Phase 1b Clinical Data Demonstrating 100% Clinical Response Regarding Efficacy Of PALI-2108 In Ulcerative Colitis
PALI-2108 demonstrated favorable safety, with no serious adverse events, lab abnormalities, or EKG concernsPhase 1b data demonstrated 100% clinical response and promising signals regarding the efficacy of PALI-2108 in
09-17 21:05
Palisades Goldcorp Updates on Capital Transaction and Warrants
Palisades Goldcorp Ltd. ( ($TSE:PALI) ) has provided an announcement. Palisades...
09-10 10:07
Palisade Bio Receives Health Canada Clearance To Initiate Phase 1b Study Of PALI-2108 In Fibrostenotic Crohn's Disease
First dual-acting anti-inflammatory and anti-fibrotic candidate in development for FSCD, a condition with no approved therapiesPatient dosing expected to commence in H2 2025; Topline data anticipated in Q1 2026Continued
09-05 20:47
Palisade Bio Receives Health Canada Clearance for Phase 1b Trial of PALI-2108 in Fibrostenotic Crohn’s Disease (FSCD)
Palisade Bio received Health Canada’s No Objection Letter for a Phase 1b clinical study of PALI-2108, a first-in-class, ileocolonic-targeted PDE4 B/D inhibitor for fibrostenotic Crohn’s disease (FSCD). FSCD lacks approved anti-fibrotic therapies, with current treatments addressing symptoms rather than the disease process. The open-label study will enroll 6-12 patients to assess safety, pharmacokinetics, pharmacodynamics, and exploratory endpoints...
09-05 12:45
Palisade Bio Releases Virtual Investor KOL Connect Segment on FSCD and Lead Candidate PALI-2108
Palisade Bio announced the release of a Virtual Investor KOL Connect segment featuring Dr. Brian Feagan, a leading expert in Fibrostenotic Crohn's Disease (FSCD) and Inflammatory Bowel Diseases (IBD). Dr. Feagan discussed the challenges with current FSCD treatments and highlighted the need for more effective therapies addressing both inflammation and fibrosis. He shared insights on PALI-2108, a novel localized approach aiming to reduce class-asso...
08-25 13:00
